Ignite Proteomics LLC, a subsidiary of IMAC Holdings, Inc., announced new findings that show MHC-II protein expression is a more reliable predictor of response to pembrolizumab (Keytruda®) than the ...
MHC class II molecules are central to the adaptive immune response, serving as the means by which antigen-presenting cells, notably dendritic cells, display processed peptides to CD4+ T cells. This ...
MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
Researchers found that T cells recognize neoself-antigens -- abnormal, unfolded host proteins presented by major histocompatibility complex II (MHC-II) lacking the invariant chain -- as non-self ...
A new study sheds light on why some patients with the most aggressive form of ovarian cancer respond better to treatment than others. Tumors positive for a molecule called MHC class II are linked to ...
Controlling infectious diseases—especially zoonoses—is critical for both the economy and public health. Developing safe, effective vaccines remains the most reliable strategy for disease control, but ...
Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
Leukogene Therapeutics, Inc., an early‑stage oncology company developing MHC class II-engager immunotherapies for immunologically cold cancers, today announced two poster presentations at the American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results